OPKO Health is a diversified healthcare company with two segments: pharmaceuticals and diagnostics. Its most important pharmaceutical asset is NGENLA (Somatrogon), a once-weekly injectable human growth hormone for children with growth hormone deficiency, which OPKO developed using its CTP technology that extends the half-life of growth hormone to allow weekly rather than daily injections. OPKO does not sell NGENLA directly — Pfizer handles all global commercialization and pays OPKO a tiered gross profit share, meaning OPKO earns more as Pfizer sells more, but has limited control over its most important revenue driver. OPKO's diagnostics business, BioReference Health, operates clinical labs primarily in the New York and New Jersey region, plus a national franchise for the 4Kscore prostate cancer risk assessment test. OPKO sold the bulk of BioReference's non-core operations to Labcorp in 2024-2025, leaving a smaller, more focused lab business. OPKO also runs pharmaceutical commercial businesses in Spain, Ireland, Mexico, and Chile, and its Irish subsidiary EirGen Pharma manufactures high-potency oral pharmaceuticals exported to over 60 countries. OPKO's pipeline is centered on its ModeX subsidiary, which is developing multispecific antibodies across oncology and immunology, with the most advanced program in Phase 1 dose escalation. OPKO also has a BARDA-funded infectious disease antibody program, an EBV vaccine partnered with Merck, and a GLP-1/glucagon dual agonist targeting obesity and liver disease. A new collaboration with Regeneron uses ModeX's platform to develop multispecific molecules across oncology, immunology, and metabolism.